サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：肝性脳症市場：薬物クラス別、投与経路別、流通チャネル別、地域別- 規模、シェア、展望、機会分析、2023～2030年
市場調査レポート
商品コード
1290574

肝性脳症市場：薬物クラス別、投与経路別、流通チャネル別、地域別- 規模、シェア、展望、機会分析、2023～2030年

Hepatic Encephalopathy Market, by Drug Class, by Route of administration, By Distribution Channel, by Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

出版日
ページ情報
英文 210 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
肝性脳症市場：薬物クラス別、投与経路別、流通チャネル別、地域別- 規模、シェア、展望、機会分析、2023～2030年
出版日: 2023年05月10日
発行: Coherent Market Insights
ページ情報: 英文 210 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

肝性脳症は、急性肝不全や肝硬変、末期肝疾患を患う患者さんの死亡原因の上位を占めています。肝性脳症を患うと、アンモニアを代謝する能力が失われ、その結果、体の様々な組織や臓器にアンモニアが蓄積されます。さらに、アンモニアは血液脳関門を通過するため、神経認知障害を引き起こします。肝性脳症は、隠蔽型肝性脳症（CHE）と顕性肝性脳症（OHE）に分類され、そのうち顕性肝性脳症は隠蔽型肝性脳症（CHET）と比較して死亡率が高く、QOLが悪いとされています。市場参入企業は、肝疾患を治療するための新しい技術や技法を開発しています。その結果、来年には市場が拡大すると思われます。

手頃な価格の肝臓関連治療オプションへのアクセスを向上させるための政府および非政府組織のイニシアチブの増加。肝臓の健康の重要性に関する人々の意識の高まりと有利な償還は、市場成長を促進する可能性が高い要因です。例えば、2022年10月、Bausch Health Companies Inc.とその胃腸科事業、最大の専門製薬会社の1つであるSalix Pharmaceuticalsは、脳に影響を及ぼす肝硬変の合併症である肝性脳症（HE）に対するICD-10コードK76.82の実装を、Centers for Medicare &Medicaid Services（CMS）から支持することを発表した

本調査の主な特徴

  • 本レポートでは、世界の肝性脳症市場を詳細に分析し、2022年を基準年とした予測期間（2023年～2030年）の市場規模および年間平均成長率（CAGR%）を提供しています。
  • さまざまなセグメントにおける潜在的な収益機会を解明し、この市場に対する魅力的な投資提案マトリクスを説明しています。
  • また、市場促進要因、抑制要因、機会、新製品の発売または承認、市場動向、地域展望、主要企業が採用する競争戦略に関する重要な考察を提供します。
  • 企業ハイライト、製品ポートフォリオ、主要なハイライト、財務実績、戦略など、以下のパラメータに基づいて、世界の肝性脳症市場の主要企業をプロファイルしています。
  • この調査の一部としてカバーされている主要企業は、ASKER Pharmaceutical Co., Ltd, Cosmo Pharmaceuticals N.V, Lupin Limited, Kaleido Biosciences, Kannalife Sciences Inc., Bausch Health Companies Inc, Ferring Pharmaceuticals In, Mallinckrodt Pharmaceuticals, Umecrine Cognition AB, Norgine B.V, Abbott Laboratories, QR Science and Technology Development Co.。
  • 本レポートの洞察により、マーケティング担当者や企業の経営陣は、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができるでしょう。
  • 世界の肝性脳症市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界のさまざまな利害関係者に対応しています。
  • 利害関係者は、世界の肝性脳症市場の分析に使用される様々な戦略マトリックスを通じて、意思決定を容易にすることができます。

目次

第1章 調査目的と前提条件

  • 調査目的
  • 前提条件
  • 略語

第2章 市場展望

  • レポート概要
    • 市場の定義と範囲
  • エグゼクティブサマリー
    • 市場スナップショット：薬物クラス別
    • 市場スナップショット：投与経路別
    • 市場スナップショット、流通チャネル別
    • 市場スナップショット：地域別
  • コヒーレント・オポチュニティ・マップ（COM）

第3章 市場力学、規制、動向分析

  • 市場力学
  • 促進要因
  • 抑制要因
  • 市場機会
  • 影響分析
  • 主な発展
  • 最近の製品発売/承認
  • 技術的背景
  • 合併、買収、共同研究のシナリオ
  • 法規制シナリオ
  • PEST分析
  • ポーターのファイブフォース分析
  • 価格分析
  • ブランド分析

第4章 肝性脳症の世界市場-コロナウイルス（COVID-19）のパンデミックの影響

  • 経済的影響
  • COVID-19の疫学
  • 需要と供給への影響

第5章 肝性脳症の世界市場：薬物クラス別、2017年～2030年

  • 抗生物質
  • 緩下剤
  • L-オルニチン・L-アスパラギン酸塩
  • その他

第6章 肝性脳症の世界市場：投与経路別、2017年～2030年

  • 経口投与
  • 静脈内投与
  • 直腸

第7章 肝性脳症の世界市場：流通チャネル別、2017年～2030年

  • 病院内薬局
  • 小売薬局
  • オンライン薬局

第8章 肝性脳症の世界市場：地域別、2017年～2030年

  • 北米
  • 米国
  • カナダ
  • ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
  • その他ラテンアメリカ
  • 欧州
  • 英国
  • ドイツ
  • イタリア
  • フランス
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋地域
  • 中国
  • 日本
  • インド
  • オーストラリア
  • ASEAN
  • 韓国
  • その他アジア太平洋地域
  • 中東地域
  • GCC
  • イスラエル
  • その他中東地域
  • アフリカ
  • 北アフリカ
  • 中央アフリカ
  • 南アフリカ共和国

第9章 競合情勢

  • ASKA Pharmaceutical Co., Ltd
  • Cosmo Pharmaceuticals N.V.
  • Lupin Limited.
  • Kaleido Biosciences
  • Kannalife Sciences Inc.
  • Bausch Health Companies Inc.
  • Ferring Pharmaceuticals Inc
  • Mallinckrodt Pharmaceuticals
  • Umecrine Cognition AB
  • Norgine B.V.
  • Abbott Laboratories
  • QR Science and Technology Development Co.

第10章 セクション

  • 調査手法について
  • 出版社について
目次
Product Code: CMI2596

Hepatic encephalopathy (HE) is the leading cause of mortality in patients suffering from acute liver failure and also in those patients suffering from liver cirrhosis and associated with end stage liver disease. A person suffering from hepatic encephalopathy loses the ability to metabolize ammonia, which results in the buildup of ammonia in various tissues and organs of the body. Moreover, ammonia crosses the blood-brain barrier, and thus causing neurocognitive impairment. Hepatic encephalopathy can be classified into two types: covert hepatic encephalopathy (CHE) and overt hepatic encephalopathy (OHE), out of which, overt hepatic encephalopathy is associated with high rates of mortality and poor quality of life, as compared to covert hepatic encephalopathy (CHET). The major market participants have developed novel technologies and techniques for treating liver disorders. The market will expand as a result in the coming year.

Increase in the government and non-government organizations initiatives to improve access to affordable liver related treatment option. Rise in the awareness regarding the importance of liver health among the people and favorable reimbursement are the factors likely drive the market growth. For instance, in October 2022, Bausch Health Companies Inc., and its gastroenterology business, Salix Pharmaceuticals, one of the largest specialty pharmaceutical companies announced the endorsement of the implementation of K76.82, an ICD-10 code from the Centers for Medicare & Medicaid Services (CMS) for hepatic encephalopathy (HE), a complication of cirrhosis that affects the brain

Key features of the study:

  • This report provides in-depth analysis of the global hepatic encephalopathy market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global hepatic encephalopathy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include ASKER Pharmaceutical Co., Ltd, Cosmo Pharmaceuticals N.V, Lupin Limited, Kaleido Biosciences, Kannalife Sciences Inc., Bausch Health Companies Inc, Ferring Pharmaceuticals In, Mallinckrodt Pharmaceuticals, Umecrine Cognition AB, Norgine B.V, Abbott Laboratories, QR Science and Technology Development Co.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global hepatic encephalopathy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hepatic encephalopathy market

Detailed Segmentation:

  • Global Hepatic Encephalopathy Market, By Drug Class:
    • Antibiotics
    • Laxatives
    • L-ornithine L-aspartate
    • Others
  • Global Hepatic Encephalopathy Market, By Route of administration:
    • Oral
    • Intravenous
    • Rectal
  • Global Hepatic Encephalopathy Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Hepatic Encephalopathy Market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
      • By Country:
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
      • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
    • ASKA Pharmaceutical Co., Ltd.
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Cosmo Pharmaceuticals N.V
    • Lupin Limited
    • Kaleido Biosciences
    • Kannalife Sciences Inc.
    • Bausch Health Companies Inc.
    • Ferring Pharmaceuticals Inc.
    • Mallinckrodt Pharmaceuticals
    • Umecrine Cognition AB
    • Norgine B.V
    • Abbott Laboratories
    • Kos Pharmaceuticals, Inc.
    • QR Science and Technology Development Co.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Class
    • Market Snapshot, By Route of Distribution
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
  • Impact Analysis
  • Key Developments
  • Recent Product Launches/Approvals
  • Technological Landscape
  • Merger, Acquisition, Collaborations Scenario
  • Regulatory Scenario
  • PEST Analysis
  • Porter's Five Forces Analysis
  • Pricing Analysis
  • Brand Analysis

4. Global Hepatic Encephalopathy Market - Impact of Coronavirus (Covid-19) Pandemic

  • Economic Impact
  • COVID-19 Epidemiology
  • Impact on Supply and Demand

5. Global Hepatic Encephalopathy Market, By Drug Class, 2017 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Antibiotics
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Laxatives
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • L-ornithine L-aspartate
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Others
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends

6. Global Hepatic Encephalopathy Market, By Route of Administration, 2017 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Intravenous
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Rectal
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Hepatic Encephalopathy Market, By Distribution Channel, 2017 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Hepatic Encephalopathy Market, By Region, 2017 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Region, 2017 - 2030, (US$ Million)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Region, 2017 - 2030, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Region, 2017 - 2030, (US$ Million)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Region, 2017 - 2030, (US$ Million)
  • China
  • Japan
  • India
  • Australia
  • ASEAN
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Region, 2017 - 2030, (US$ Million)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Region, 2017 - 2030, (US$ Million)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • ASKA Pharmaceutical Co., Ltd
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Cosmo Pharmaceuticals N.V.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Lupin Limited.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Kaleido Biosciences
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Kannalife Sciences Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Bausch Health Companies Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Ferring Pharmaceuticals Inc
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Mallinckrodt Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Umecrine Cognition AB
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Norgine B.V.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Abbott Laboratories
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • QR Science and Technology Development Co.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies

10. Section

  • Research Methodology
  • About Us